Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like Insys Settles With Illinois for $4.5 Million for Deceptive Opioid Marketing August 21, 2017 EU Court Maintains Suspension of EMA Document Release March 17, 2017 Alcon Snags Aerie Pharmaceuticals and Its Prescription Eyedrop Portfolio August 23, 2022